1. Revolutionizing Neurology with Cutting-Edge Technology

NMTC is revolutionizing brain technology with its advanced ultra-thin electrodes that can interface with more neurons by reducing the size of the contacts. This breakthrough enables more precise communication within the brain, enhancing the potential for diagnosing and treating neurological disorders. Additionally, NMTC's technology offers a minimally invasive approach to back pain treatment, allowing a film electrode to be placed through a needle in the spine to stimulate broader areas without the need for incisions.

This cutting-edge technology is also a game-changer for pharmaceutical companies, as it enables the precise location of specific areas in the brain for the delivery of gene and cell-based therapies, while simultaneously monitoring their effects. No other technology on the market provides this level of precision.

NMTC will be presenting at a prominent pain meeting in late September, where Dr. Sean Li will showcase the technology, calling it "The Next Big Thing."

2. NMTC vs. Neuralink: A Real Contender in the Neurotech Race

While Elon Musk's Neuralink is making headlines for its bold vision, it’s NMTC that’s already FDA-cleared. Neuralink is still awaiting approval, while NMTC's technology is already in use at top academic hospitals across the U.S. And with Neuralink valued at a staggering $8 billion despite having no commercial revenue, NMTC—already generating revenue and establishing commercial deals—could be the true hidden gem in this space.

3. FDA-Approved and Commercially Deployed

NMTC's technology isn’t just a concept; it’s real, and it’s already helping patients. The company has three FDA-cleared products, currently being used in some of the nation’s leading hospitals. With revenue flowing and a commercial agreement with a global medical device giant, NMTC is setting itself apart from other neurotech startups still trying to get off the ground.

4. Strategic Partnership with a $25 Billion Powerhouse

In 2020, NMTC forged a strategic partnership with Zimmer Biomet, a $25 billion market cap titan in the medical device industry. Zimmer Biomet is now distributing NMTC’s breakthrough diagnostic product for epilepsy, opening massive doors in the medical community. This partnership isn’t just a deal; it’s a game-changer.

5. Big Moves on the Horizon